banner2

Getting started
Sulfobutylether beta-Cyclodextrin

Sulfobutylether beta-Cyclodextrin - China Manufacturers, Suppliers, Factory

Sulfobutylether beta-Cyclodextrin, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

SBE-β-CD CAS 182410-00-0 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — SBE-β-CD CAS 182410-00-0 Betadex Sulfobutyl Ether Sodium Assay 95.0~105.0%
Read More

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

D-3-Cyanophenylalanine CAS 263396-43-6 Assay ≥98.0% (HPLC)

banner1

Top Selling Products

Related Blog
Reviews

The 3rd China International Biological & Chemical Pharmaceutical Industry Conference

The 3rd CMC-China 2021 Time: September 29-30, 2021 Exhibition Venue: C-D Hall, Suzhou International Expo Center, Suzhou City, JIangsu Province, China. Synergy of Centralized China’s Drug Volume-ba...
Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...

2022.10.25 20:18:50
2022.09.06 19:00:59
2022.06.08 08:12:35
2022.03.05 18:50:03
2022.02.03 21:14:06
2021.10.25 10:37:52

related search